Fig. 2

Patient selection and study cohort derived from the Patient360 NSCLC database. 1L, first line; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; IO, immunotherapy; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase. ^aStage 3 (3B, 3C) or neoplasm, secondary; ^bStage 4, M1 or neoplasm, metastatic